Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guilford

Executive Summary

Fourth quarter revenues from sales of the company's Gliadel wafer glioma therapy are projected to be $1.8 mil. in transfer sales and royalties, $700,000 of which are royalties alone, Guilford CEO Craig Smith, MD, told analysts Jan. 12. The company has plans to continue to build Gliadel sales with two potential new indications and a high dose version of the BCNU-containing polymer implant. Guilford and partner Rhone-Poulenc Rorer are conducting a Phase III trial for Gliadel as a first-line therapy, and a Phase II metastatic brain cancer trial
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel